



Advanced Research of Oncogene and Therapy Targets in Human Cancers

Guest Editor:

Dr. Zhongqiu Xie

Department of Pathology,
University of Virginia,
Charlottesville, VA, 22903, USA

Deadline for manuscript
submissions:

closed (29 February 2024)

Message from the Guest Editor

Cancer arises through a multistep, mutagenic process whereby cancer cells acquire a common set of properties, including unlimited proliferation potential, self-sufficiency in growth signals, and resistance to antiproliferative and apoptotic cues. Cancer cell dependency on single oncogenes has been explored for drug discovery, leading to the development of targeted therapies. Oncogene addiction strongly impacts the therapeutic response of tumors to acute oncoprotein inhibition. However, the mechanism by which cancer cells become dependent on a single pathway or activated oncoprotein is not precisely understood in most cases. Thus, a better understanding of oncogene may provide a rationale for improving current cancer therapies and aid in the development of novel therapeutic strategies for the management of cancer. This Special Issue of Biomedicines focuses on recent advances in this area, with a goal to stimulate advanced research and clinical interest in the exciting field of oncogene and therapy targets in human cancers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)